Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

Authors
Ryden L.
Nicholls S.
Grobbee D.
Lincoff A.
Tardif J-C.
Schwartz G.
Malmberg K.
Buse J.
Henry R.
Wedel H.
Weichert A.
Cannata R.
Neal Bruce
Type of Publication
Journal Article
Year of Publication
2013
Journal
American Heart Journal
Language
Eng
Volume
166
Number of Pages
429-34.
Links to full text
Search Publications